OVARIAN CANCER and US: DPX-0907

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label DPX-0907. Show all posts
Showing posts with label DPX-0907. Show all posts

Friday, April 15, 2011

PR-USA - Immunovaccine Reports Positive Interim Data from Phase I Clinical Trial of DPX-0907 in Patients With Ovarian Cancer



"....The ongoing Phase I clinical trial of DPX-0907 is an open-label, dose-escalating evaluation of the vaccine's safety and tolerability in patients with advanced breast, ovarian or prostate cancer. Immunovaccine developed DPX-0907 with seven peptide antigens designed to target multiple cancer pathways.
Enrollment in the study has been completed. This preliminary evaluation examined vaccine responses in the first fifteen patients enrolled in the study; three with breast cancer, five with ovarian cancer and seven with prostate cancer. Immunovaccine will perform a more detailed analysis of samples collected from all patients by Q3 2011. Patients received three injections (0.25 mL or 1 mL) of the active immune therapy DPX-0907........"

Tuesday, March 30, 2010

Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine - MarketWatch



press release
March 29, 2010
Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine

HALIFAX, NOVA SCOTIA, Mar 29, 2010 -- Immunovaccine Inc. today announced that it has started screening patients for its Phase 1 clinical trial, investigating the company's therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is to establish the safety of the vaccine candidate which includes the DepoVax(TM) delivery platform. Secondary goals include an evaluation of dosing and an assessment of immune response.